Welcome to Dwaey, specifically on Flunarizine page.
This medicine contains important and useful components, as it consists of
Flunarizine is available in the market in concentration.
Flunarizine
Flunarizine is a calcium channel blocker primarily used for the prevention of migraines and for managing symptoms of vertigo and motion sickness. Before prescribing this medication, it is essential to consider the patient's history of depression, as flunarizine can cause or exacerbate depressive symptoms in some individuals. Patients with a history of depression or those currently taking antidepressants should be closely monitored. Flunarizine should be used cautiously in patients with a history of Parkinson’s disease or other extrapyramidal disorders because it may exacerbate symptoms, particularly in elderly patients. Additionally, flunarizine can cause weight gain and sedation, so patients should be advised to monitor their weight and avoid engaging in activities that require full alertness, such as driving or operating heavy machinery, especially when starting treatment. Liver and kidney function should be assessed before initiating therapy, as impaired organ function may require dose adjustments. As with any central nervous system (CNS) depressant, concurrent alcohol use should be avoided to reduce the risk of enhanced sedative effects. Pregnant or breastfeeding women should consult a healthcare provider before using flunarizine, as its safety in these populations has not been well established.
Flunarizine is mainly indicated for the prophylactic treatment of migraines and the management of vestibular disorders, such as vertigo and motion sickness. It is also used to prevent or reduce the severity of symptoms in conditions like Meniere’s disease, a disorder of the inner ear that causes vertigo, tinnitus, and hearing loss. Flunarizine has demonstrated efficacy in preventing migraines by stabilizing calcium ion fluxes within nerve cells, thereby reducing excitability and preventing migraine attacks. In addition to its use in migraines and vertigo, flunarizine is also sometimes used off-label for the management of other conditions such as tension-type headaches or to aid in the treatment of epilepsy in certain cases, though these uses may vary based on regional guidelines and medical practices. Flunarizine is also occasionally used in the management of some movement disorders, though this is typically in specialized settings.
Flunarizine is contraindicated in patients with known hypersensitivity to the drug or any of its components. It is also contraindicated in individuals with Parkinson's disease or other movement disorders due to its potential to worsen symptoms, such as tremors and rigidity. Patients with a history of depression should be cautious, as flunarizine can exacerbate depressive symptoms, and it may not be suitable for those with major depressive disorders. Flunarizine should not be used in patients with a history of or active liver disease (e.g., cirrhosis or hepatitis) as it is metabolized in the liver, and impaired liver function may lead to increased levels of the drug and subsequent toxicity. In patients with severe renal impairment, flunarizine should be avoided, as the drug is primarily excreted through the kidneys. Additionally, flunarizine is contraindicated during pregnancy unless the benefits outweigh the risks, as its safety during pregnancy has not been adequately studied. It is also not recommended for use in breastfeeding mothers, as it is excreted in breast milk and could potentially affect the infant.
The side effects of flunarizine are generally mild but can vary in intensity. Common side effects include sedation, drowsiness, and weight gain. These effects are usually most pronounced during the initial phase of treatment and often diminish over time as the body adjusts to the medication. Other possible side effects include dry mouth, constipation, and abdominal discomfort. Some patients may experience dizziness, especially when standing up quickly, or other symptoms related to hypotension. In rare cases, flunarizine can cause extrapyramidal symptoms such as tremors, rigidity, and bradykinesia, particularly in older patients or those with pre-existing movement disorders. Depression is another potential side effect, as flunarizine has been associated with mood changes in some individuals. If symptoms of depression, such as sadness, hopelessness, or suicidal thoughts, arise, the medication should be discontinued, and alternative treatments should be explored. More serious, but rare, side effects include liver enzyme abnormalities, and in some cases, liver toxicity. If signs of liver dysfunction, such as jaundice or dark urine, occur, the drug should be discontinued immediately. Long-term use of flunarizine may also contribute to weight gain, which could be a concern for some patients, particularly those with a predisposition to obesity or those with comorbid conditions such as diabetes.
Flunarizine is a calcium channel blocker that works by inhibiting the entry of calcium ions into vascular smooth muscle and neurons. By blocking calcium influx, flunarizine reduces vascular tone and decreases the excitability of neurons. This is particularly beneficial in preventing migraine attacks, as it helps to stabilize the activity of neurons in the brain and prevents the abnormal nerve signaling that can lead to the intense pain associated with migraines. The drug’s action on calcium channels also extends to the vestibular system, where it can help reduce the symptoms of vertigo by inhibiting excessive neuronal activity in the inner ear and the brainstem. This makes it effective in treating vestibular disorders, such as Meniere's disease. By reducing calcium influx, flunarizine helps to stabilize both vascular and neuronal function, providing symptomatic relief in conditions related to abnormal neural or vascular activity. The drug's ability to affect both the central and peripheral nervous systems is what makes it effective in the treatment of migraines and other related conditions.
Flunarizine may interact with a variety of medications, potentially altering their effects. For example, flunarizine can enhance the sedative effects of other CNS depressants, such as alcohol, sedatives, and antihistamines, leading to increased drowsiness or impaired motor coordination. Patients should avoid alcohol while using flunarizine, especially when starting the medication or when the dose is adjusted. Flunarizine can also interact with other antihypertensive medications, particularly those that affect calcium channels, potentially leading to enhanced hypotensive effects. The drug may also interact with antidepressants, especially tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs), leading to an increased risk of sedation or other side effects. Concomitant use with other antiepileptic medications may lead to reduced effectiveness or an increased risk of adverse effects. It is important to inform the prescribing physician of all medications the patient is taking, including over-the-counter drugs, to avoid potential interactions. Careful monitoring is advised when flunarizine is used in combination with any other medications that affect the central nervous system or the cardiovascular system.
The usual adult dose of flunarizine for migraine prevention is 10 mg once daily, typically taken in the evening. This low dose helps to minimize the sedative effects commonly associated with the drug. If a satisfactory response is not achieved, the dose may be increased to 20 mg once daily, although higher doses are generally not recommended. For the treatment of vertigo or motion sickness, the starting dose is usually 5 mg to 10 mg per day, depending on the severity of symptoms, with a typical maintenance dose of 10 mg daily. In some cases, the dosage can be adjusted based on individual patient response. It is important that patients begin treatment at the lowest effective dose to minimize the risk of sedation and other side effects, particularly in the elderly. The medication should be taken at the same time each day to ensure consistent effectiveness.
Flunarizine is generally not recommended for use in children under the age of 18 for migraine prevention or vertigo unless specifically prescribed by a healthcare provider. Pediatric dosing is not well-established, and the drug has not been extensively studied in the pediatric population. In cases where flunarizine is considered for off-label use in children, the dose should be carefully determined by a healthcare provider based on the child's weight, the condition being treated, and their overall health status. Pediatric patients should be closely monitored for any side effects, especially those related to sedation, mood changes, and potential weight gain. Alternative treatments for pediatric migraine and vertigo are generally preferred.
Flunarizine is primarily metabolized in the liver and excreted in the urine, so dose adjustments are typically not necessary for patients with mild to moderate renal impairment. However, in patients with severe renal impairment, flunarizine should be used with caution due to the potential for reduced clearance and an increased risk of drug accumulation. In such cases, careful monitoring of renal function is advised, and the dose should be adjusted based on the patient's clinical response. It is recommended that flunarizine be used at the lowest effective dose in patients with significant renal dysfunction, and alternative treatments should be considered if necessary.
Not available in a medicine form yet